Xilio Therapeutics nabs $95m Series C

Xilio Therapeutics, a developer of immunotherapies for cancer patients, has raised $95 million in Series C financing.

Xilio Therapeutics, a developer of immunotherapies for cancer patients, has raised $95 million in Series C financing. Rock Springs Capital led the round with participation from other investors that included Bain Capital Life Sciences, Deerfield Management and RA Capital Management.

Source: Press Release